Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

DISEASE CHARACTERISTICS:

Inclusion criteria:

Histologically confirmed non-small cell lung cancer

Stage I-IIIA disease
Must have undergone a complete resection
Must begin adjuvant chemotherapy within 8 weeks of surgical resection

PATIENT CHARACTERISTICS:

Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Absolute neutrophil count ≥ 1,500/mm^3
Hemoglobin ≥ 8.0 g/dL
Platelet count ≥ 100,000/mm^3
Serum creatinine normal OR creatinine clearance ≥ 40 mL/min
Bilirubin normal

Alkaline phosphatase (AP), Aspartate aminotransferase (AST), and Alanine transaminase (ALT) must meet 1 of the following criteria:

AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)
AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN
AP ≤ 5 times ULN AND AST and ALT normal
Negative pregnancy test
Fertile patients must use effective contraception during and for at least 3 months after study therapy

Exclusion criteria:

Patients with a history of severe hypersensitivity to docetaxel or polysorbate 80 are excluded.
Women who are currently or planning to breast feed.
Those with peripheral neuropathy ≥ grade 2

PRIOR CONCURRENT THERAPY:

2-8 weeks since prior surgery and recovered